Elanco Animal Health Enters Material Definitive Agreement

TL;DR

Elanco just signed a big deal, could affect finances.

AI Summary

Elanco Animal Health Inc. entered into a material definitive agreement on July 3, 2024, related to a direct financial obligation. The company, headquartered in Greenfield, Indiana, filed an 8-K report detailing this event. Specific details of the agreement, including the nature of the financial obligation and any associated dollar amounts, are not fully disclosed in the provided text but are indicated as material.

Why It Matters

This filing indicates a significant financial commitment or obligation for Elanco Animal Health, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement and a direct financial obligation, suggesting potential financial risks or opportunities that are not fully detailed.

Key Players & Entities

• Elanco Animal Health Inc. (company) — Registrant
• July 3, 2024 (date) — Date of Earliest Event Reported
• Greenfield, Indiana (location) — Principal Executive Offices
• 877-352-6261 (phone_number) — Registrant's telephone number

FAQ

From the Filing

0001104659-24-077840.txt : 20240703 0001104659-24-077840.hdr.sgml : 20240703 20240703172350 ACCESSION NUMBER: 0001104659-24-077840 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240703 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240703 DATE AS OF CHANGE: 20240703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 241100971 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 8-K 1 tm2418797d1_8k.htm FORM 8-K false 0001739104 0001739104 2024-07-03 2024-07-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES   SECURITIES AND EXCHANGE COMMISSION WASHINGTON , D. C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934     Date of Report (Date of Earliest Event Reported): July 3, 2024   Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter)   Indiana   001-38661   82-5497352 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   2500 Innovation Way Greenfield , Indiana (Address of principal executive offices)   46140 (Zip Code)   Registrant’s telephone number, including area code: ( 877 ) 352-6261   Not Applicable (Former Name or Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, no par value   ELAN   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   ¨  Emerging growth company   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 1.01 Entry Into a Material Definitive Agreement.   On July 3, 2024, Elanco Animal Health Incorporated (the “Company”) entered into Amendment No. 2 to its Credit Agreement (as amended, the “Credit Agreement”), by and among the Company, as borrower, Elanco US Inc., as co-borrower, the subsidiary loan parties party thereto, the revolving facility lenders and the issuing banks party thereto, certain exiting revolving facility lenders, JPMo